Status:
COMPLETED
The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity
Lead Sponsor:
The Leeds Teaching Hospitals NHS Trust
Conditions:
Acute Macular Degeneration
Eligibility:
All Genders
60-99 years
Phase:
NA
Brief Summary
Currently the best treatment for "wet" macular degeneration involves regular injections of Ranibizumab (Lucentis). In the initial clinical trials, the drug was injected into the eye every month. Since...
Eligibility Criteria
Inclusion
- Patients over 60 years with a clinical diagnosis of neovascular age-related macular degeneration (ARMD), receiving treatment with intra-vitreal ranibizumab in accordance with current UK practice
- At least 6 months of prior treatment beyond the loading phase of three fixed injections
- At least 2 injections during the prior 6 months of the maintenance phase of treatment
- Early Treatment for Diabetic Retinopathy Study (ETDRS) chart letter score at 2m of between 30 and 70 letters at the start of the study
Exclusion
- Patients with chronic intra-retinal cycts or sub-retinal fluid in the study eye on Optical coherence tomography (OCT) examination despite prior treatment and judged to be stable without the need for further treatment
- Significant hearing impairment, felt likely to interfere with training and the telephone calls prior to the home monitoring
- Lack of informed consent
Key Trial Info
Start Date :
April 1 2012
Trial Type :
INTERVENTIONAL
End Date :
October 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02304068
Start Date
April 1 2012
End Date
October 1 2012
Last Update
August 20 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.